CEO Clay Siegall Elaborates the Growth of Seattle Genetics

Clay Siegall, chief executive officer at Seattle Genetics spoke to Business Journal in March 2016 about the growth of the biotechnology company from 2015 through 2016. Siegall said the company is in the process of developing 12 new drugs and hiring 120 additional employees before the end of this year. The company is already testing its commercial drug, Adcetris for cancer treatments and more than 70 trials to treat different types of lymphomas. Siegall also released information about the company’s advanced clinical trial of the drug to treat Hodgkin lymphoma. Adcetris trials will have an enormous influence on Seattle Genetics once all results are examined carefully.

According to a guidance correspondence to the company’s investors, the drug generated approximately $226 million in net sales in the United States. Adcetris sales in Canada are forecasted to reach up to $275 million from 2015 to the end of 2016. Partnering company of Seattle Genetics, Takeda Pharmaceutical also markets the drug in other countries beside Canada and the U.S. Adcetris is the first commercial drug developed by Seattle Genetics.

Seattle Genetics was co-founded in 1998 by, CEO, chairman and president, Clay Siegall. After earning his BA degree and PhD degree from University of Maryland and George Washington University, Siegall worked at the National Cancer Institute, Bristol Myers, National Institutes of Health, and Squibb Pharmaceutical. Dr. Siegall holds 15 patents and has published over 70 works as an acclaimed author. A new drug, Alcanza is developed by the company with plans of getting it into phase three clinical trials in 2016 to treat AML (acute myeloid leukemia).

Siegall also mentioned to Business Journal the company is releasing data about three new drugs to treat bladder cancer and breast cancer. By the end of this year, he said the company will add 100 employees to the headquartered office in Bothell, Washington. Approximately 20 employees will be added to the Seattle Genetics office in Switzerland. The company is meeting its desired goal noted in its 2016 second quarter financial report to expand Adcetris opportunities.

Seattle Genetics Is Prime For Expansion After Stock Boost

Seattle Genetics (SGEN) is expecting massive funding growth, according to a report in The Bothell-based biotech outfit recently announced that the $480 million stock offering is being boosted up to $582 million.

Company CEO Clay Siegall said vigorous investor interest is the primary reason for the increase. He also noted that the funds will go further than just developing cancer drugs. The company will also see an expansion in infrastructer and hiring.

Siegall says he expects at least 500 people to be hired by 2020. To accommodate the increasing workforce, the company is leasing other spaces in the Bothell area.

“We are definitely on the incline,” said Siegall. “I fully expect to have even more buildings in the near future.”

Founded in 1998, Seattle Genetics is one of the most reputable and successful biotech companies in the Puget Sound area.


“The fact that we are not turning a great profit right now, is not a major concern. That will definitely happen down the road.”

Many biotech companies take some time before they see a profit. In the interim, Seattle Genetics is focusing on expanding the use for the cancer drug Acedtris.

Clay Siegall is a the founder and CEO of Seattle Genetics. The company targets the development of drugs for cancer treatment. The company holds dozens of patents and has entered into partnerships with other companies including Glaxo Smith Kline, Pfizer and Genetech.

Siegall has received numerous awards for medicine. He graduated from the University of Maryland with a bachelors in biology. He has Phd. in genetics from George Washington University.

Dr, Clay B. Siegall’s appointment as the Mirna Therapeutics’s board of directors’ external director

Mirna Therapeutics Inc, a biotechnology company that specializes in growth and commercialization of miRNA therapeutics appointed Clay Siegall, CEO, president, co-founder and chairperson of Seattle Genetics’ board of directors as its board of directors’ external director. This appointment was due to Siegall’s vast experience in the pharmaceutical sector and his achievements in developing leading oncology company. Mirna Therapeutics is situated in Austin, Texas.
miRNAs are about 20-25 nucleotides long that interact with messenger RNAs to affect the gene expression. miRNAs coordinate the expression of several genes and guide proper embryonic growth, inflammation, cellular growth, immunity, and proliferation. This helps meet patients’ cancer needs.

About Seattle Genetics
Seattle Genetics was founded in 1998 as a foundation of precise research, scientific innovation, as well as drug development practices. The company has a mission to help cancer patients. Seattle Genetics has acquired different strategic licenses to practice ADC technology through a partnership with companies such as GlaxoSmithKline, Genentech (Roche), Pfizer and Abbvie. Dr. Siegall, the company’s co-founder, CEO, president and chairperson board of directors has led the company to capital-raising activities, to attaining over $675 million via private and public funding, as well as the firm’s first public offering back in 2001.

About Clay Siegall
Clay B. Siegall, Ph.D. is currently the CEO and chairman, Seattle Genetics, Inc and co-founded this company in 1998. Dr.Siegall pursued Bachelor of Science, Zoology in the University of Maryland, and acquired a Ph.D. in genetics from The George Washington University. He has led Seattle Genetics to its present leadership point in the development of antibody-drug conjugates for cancer treatment.
Dr.Siegall has served in different capacities including:
• President and CEO, Seattle Genetics from 1998 to present.
• Chairman, the board of directors, Alder Biopharmaceuticals, Inc from 2006 to present.
• Chairman, the board of directors, Mirna Therapeutics, Inc from 2013 to present.
• Director for the board of directors, Ultragenyx Pharmaceutical from 2014 to present.